Top 21 Stocks for 2026: My Complete Stock Picks Across 7 Categories
Discover 21 carefully selected stocks across 7 categories for 2026. From AI infrastructure to consumer staples — systematic investing for generational wealth.
Data. Logic. Profits.
Discover 21 carefully selected stocks across 7 categories for 2026. From AI infrastructure to consumer staples — systematic investing for generational wealth.
My 2026 market outlook for family investors. VIX at 6-month lows, January recovery odds, and why smart money is positioning now. Here's what I'm watching.
Meta, Netflix, Adobe, and Salesforce keep falling. I dug into the short interest data. Three are unloved. One is a genuine warning sign.
Which stocks are stretched beyond fair value? Quantitative analysis of 15 positions trading at 80-192% premium including LYFT, SoFi, CrowdStrike, and Lam Research. Risk management insights.
While everyone chases last year's winners like Micron (+213%), these 7 quality stocks are sitting at BuyTrigger levels with fresh 2026 catalysts. NVDA, META, AMZN, UBER, VRT, TSM, EQT.
Discover 21 carefully selected stocks across 7 categories for 2026. From AI infrastructure to consumer staples — systematic investing for generational wealth.
Nvidia just acquired Groq for $20B cash. What is Groq, why did Jensen pay 3x valuation, and what does it mean for $NVDA investors? Full breakdown inside.
My 2026 market outlook for family investors. VIX at 6-month lows, January recovery odds, and why smart money is positioning now. Here's what I'm watching.
VIX at 16.73 signals danger ahead. Dr. Alex Koh's 4-move summer strategy for family investors: when to hold, when to wait, and how to prepare for the last dip.
SMH semiconductor breakout imminent, but systematic analysis shows $251 BuyTrigger could fire first. Why patience beats FOMO after 13 months of sideways action.
Discover BuyTrigger: a systematic investing method that removes emotions from stock purchases. Learn when to buy with clear price targets and valuation triggers.
Discover our top 4 stock picks for May 2025 using the Pyramid Diversification strategy. Balance risk and growth with UNH, GOOGL, JPM, and LLY for market-beating returns.
Hims & Hers Health (HIMS) shows exceptional 95% revenue growth but trades well above our $34 BuyTrigger price. Discover our complete analysis and investment approach for this B+ rated high-risk opportunity.
Join the exclusive one off May 2025 Trial